Literature DB >> 14567159

The management of the obese diabetic patient.

Jeanine Albu1, Nazia Raja-Khan.   

Abstract

The prevalence of obesity and diabetes is increasing in the United States and worldwide. These diseases are predicted to explode to epidemic proportions, unless appropriate counteractive measures are taken. Several large studies (DCCT, UKPDS, Kumamoto) clearly showed that intensive glycemic control in the diabetic patient reduced microvascular complications and improved mortality. Despite this, the NHANES III showed that only 50% of diabetics have been able to achieve a HgbAic level that is less than 7%; this suggests the need for a re-evaluation of our approach to these patients. The management of the obese diabetic patient involves glycemic control and weight reduction. These goals are particularly difficult to achieve in the obese diabetic patient because progressive beta-cell dysfunction and increasing insulin resistance necessitates the administration of increasingly higher dosages of insulin, which, in turn, promotes weight gain. A vicious cycle may ensue. Lifestyle modifications with diet and exercise are an essential part of the management of the obese diabetic patient. These measures alone are often insufficient and concomitant pharmacologic therapy is usually required to achieve glycemic and weight control. Oral agents that improve glycemia, decrease insulin resistance, and limit weight gain are desirable. Because of the progressive nature of diabetes, glycemic control with monotherapy often deteriorates over time, which necessitates the addition of other pharmacologic agents, including insulin. When insulin therapy is required in the treatment of the obese diabetic patient, combinations with oral agents that have been shown to minimize the amount of exogenous insulin that is required, may minimize weight gain. In addition, the obese diabetic patient who is poorly controlled with maximum oral hypoglycemic therapy may benefit from weight-reducing agents, such as sibutramine or orlistat. The introduction of these agents at other points in the management of the obese diabetic patients have been successful. Finally, for the severely obese diabetic patient, bariatric surgery may be the only effective treatment. Gastric bypass has been unequivocally shown to produce significant weight loss and improve glycemic control on a long-term basis in the obese diabetic patient. It is recommended that physicians avail themselves of all of these strategies in the management of the obese patient who has type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14567159     DOI: 10.1016/s0095-4543(03)00043-5

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  15 in total

Review 1.  Current and novel approaches to the drug therapy of obesity.

Authors:  Jean-Philippe Chaput; Angelo Tremblay
Journal:  Eur J Clin Pharmacol       Date:  2006-08-26       Impact factor: 2.953

2.  Modifications of coronary risk factors.

Authors:  Jeanine Albu; Sheldon H Gottlieb; Phyllis August; Richard W Nesto; Trevor J Orchard
Journal:  Am J Cardiol       Date:  2006-04-19       Impact factor: 2.778

3.  Utilities and disutilities for attributes of injectable treatments for type 2 diabetes.

Authors:  Kristina S Boye; Louis S Matza; Kimberly N Walter; Kate Van Brunt; Andrew C Palsgrove; Aodan Tynan
Journal:  Eur J Health Econ       Date:  2010-03-12

4.  Prevalence and risk factors of chronic complications among patients with type 2 diabetes mellitus in Morocco: a cross-sectional study.

Authors:  Houda El Alami; Imane Haddou; Ghizlane Benaadi; Mustapha Lkhider; Driss El Habchi; Lahcen Wakrim; Naima Nabih; Omar Abidi; Naima Khlil; Abderrahmane Maaroufi; Abderrahim Naamane; Salsabil Hamdi
Journal:  Pan Afr Med J       Date:  2022-03-08

5.  Patient treatment satisfaction after switching to NovoMix® 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors.

Authors:  Meryl Brod; Paul Valensi; Joseph A Shaban; Don M Bushnell; Torsten L Christensen
Journal:  Qual Life Res       Date:  2010-07-04       Impact factor: 4.147

Review 6.  Psychological insulin resistance: patient beliefs and implications for diabetes management.

Authors:  Meryl Brod; Jens Harald Kongsø; Suzanne Lessard; Torsten L Christensen
Journal:  Qual Life Res       Date:  2008-11-28       Impact factor: 4.147

7.  Glucose tolerance in the proximal versus the distal small bowel in Wistar rats.

Authors:  Marcus Vinicius Dantas de Campos Martins; Antônio Augusto Peixoto; Alberto Schanaider; Christiano Costa Esposito; Carolina Barreira Albano Aratanha
Journal:  Obes Surg       Date:  2008-08-22       Impact factor: 4.129

8.  Utilities and disutilities for type 2 diabetes treatment-related attributes.

Authors:  Louis S Matza; Kristina S Boye; Nicole Yurgin; Jessica Brewster-Jordan; Sally Mannix; Jodi M Shorr; Beth L Barber
Journal:  Qual Life Res       Date:  2007-07-19       Impact factor: 4.147

Review 9.  Insulin therapy and type 2 diabetes: management of weight gain.

Authors:  Samy I McFarlane
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-10       Impact factor: 3.738

Review 10.  Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.

Authors:  R Balena; I E Hensley; S Miller; A H Barnett
Journal:  Diabetes Obes Metab       Date:  2012-11-12       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.